Technical Analysis for NUVL - Nuvalent, Inc.

Grade Last Price % Change Price Change
D 22.86 -12.31% -3.21
NUVL closed down 12.31 percent on Friday, September 24, 2021, on 62 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Down
Historical NUVL trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -12.31%
NR7 Range Contraction -12.31%
Wide Bands Range Expansion -12.31%
Older End-of-Day Signals for NUVL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 10% about 15 hours ago
60 Minute Opening Range Breakdown about 19 hours ago
Down 5% about 20 hours ago
Down 3% about 20 hours ago
Fell Below Previous Day's Low about 20 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Nuvalent, Inc. Description

Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Chemical Compounds Organic Compounds Tyrosine Kinase Receptors Preclinical Stage Biopharmaceutical Therapies For Patients With Cancer Entrectinib

Is NUVL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 40.715
52 Week Low 17.0
Average Volume 233,394
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 34.91
10-Day Moving Average 33.12
Average True Range 3.07
ADX 46.56
+DI 14.38
-DI 31.62
Chandelier Exit (Long, 3 ATRs) 31.49
Chandelier Exit (Short, 3 ATRs) 32.07
Upper Bollinger Bands 43.62
Lower Bollinger Band 26.19
Percent B (%b) -0.19
BandWidth 49.93
MACD Line 0.24
MACD Signal Line 2.45
MACD Histogram -2.2191
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.77
Resistance 3 (R3) 28.31 27.21 26.95
Resistance 2 (R2) 27.21 25.96 26.94 26.67
Resistance 1 (R1) 25.04 25.19 24.49 24.50 26.40
Pivot Point 23.94 23.94 23.67 23.67 23.94
Support 1 (S1) 21.77 22.69 21.22 21.23 19.32
Support 2 (S2) 20.67 21.92 20.40 19.05
Support 3 (S3) 18.50 20.67 18.77
Support 4 (S4) 17.96